Breast Cancer
It is among the fearful dreams of women. It is important to check regularly and apply treatment accordingly. According to a statement from the United States, thanks to the hormone receptor developed for positive cancers, breast cancer deaths have been significantly reduced with screening and treatments.
The United States, which has played an important role in the approval of 30 anticancer drugs in the last 10 years with therapeutic advances, states that this has prevented deaths. TheCancer Intervention and Surveillance Modeling Network (CISNET) continues to develop models for breast cancer screening and stage-specific treatment. Especially metastatic breast cancers are planned to be prevented to a great extent.
Since 1975, many models have been used in research on the dependence of estrogen receptor (ER) and ERBB2 (HER2) on mortality in women aged 30-79 years. In addition to deaths, survival rates from metastatic cancers were also analyzed through these models.
Decrease in Breast Cancer Deaths
In this study, which compared women withmalignant breast tumors with women without this type of tumor, the following existing patients were examined:
- Screening only, with no diagnostic or therapeutic intervention,
- Treatment for stages I-III,
- Screening and treatment for metastatic forms
- The combined effect of all of these options
Comparing breast cancer death rates in 1975 and 2019, in 1975 there were 48 deaths per 100,000 women in the US. In 2019, it dropped to 27 per 100,000. This represents a 58% reduction in mortality (overall deaths) (ranging from 55% to 61% depending on the model). Compared to the ER-/ERBB2- forms, there was a reduction of approximately 71% (68%-76%) (35%-42%).
Breast Cancer Screening and After Treatment
Improvements in breast cancer screening and stage I-III treatment in the United States between 1975 and 2019 led to a reduction in deaths, according to research models conducted by CISNETT. In addition, death rates in metastatic forms fell further in association with improved therapeutic management. About 25% of the observed decline was attributed to treatment of metastatic forms, another 25% to screening and about 50% to therapeutic advances in early-stage forms (stages I-III).
However, CISNET warns that the analysis of these simulations does not address disparities in age, gender, cost, etc.
